Cardiovascular · Calcium Channel BlockerRegulatory Approvalcommercialnear-term

FDA Approves ANDA for Verapamil Hydrochloride by Knack

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/29/2026, 6:31:30 AM

Assessment confidence: 64% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's approval of Knack's ANDA for Verapamil Hydrochloride introduces a new competitor in the cardiovascular market. This could impact existing players' market share and pricing strategies, necessitating a proactive response from portfolio teams. Regulatory context from FDA (FDA AP — VERAPAMIL HYDROCHLORIDE (ORIG)) supports the near-term read. Assessment grounded in 27 ranked evidence items (11 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this approval on existing products and consider strategies to maintain market share. The strongest clinical anchor is A Phase I Clinical Trial to Evaluate the Pharmacokinetic and Safety of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Mild Hepatic Impairment, Moderate Hepatic Impairment, and No (ClinicalTrials.gov), moderate corpus alignment. In Cardiovascular · Calcium Channel Blocker, 8 regulatory and 4 competitive items passed relevance filtering for Knack.

Competitive Pressure

The most relevant competitive pressure comes from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need (Pfizer) — sponsor/company relevance (pfizer). FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — VERAPAMIL HYDROCHLORIDE (ORIG) (FDA). Entity match (knack); Regulatory pathway relevance (nda). The approval of ANDA220076 indicates compliance with FDA standards, but does not suggest immediate regulatory changes for existing products.

Key Risks

Clinical risk from ClinicalTrials.gov (Cardiometabolic Effects of the Recommended Daily Pecan Intake Dose) could weigh on Knack through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

The entry of Knack into the Verapamil market may lead to increased competition, potentially affecting revenue and market positioning for current players in the cardiovascular segment.
Upside for Knack may improve if An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio teams should assess the impact of this approval on existing products and consider strategies to maintain market share.

What Would Change This Assessment

This becomes more urgent if Monitor market entry timing and initial sales performance of Knack's Verapamil Hydrochloride.
Timeline shift beyond near term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — VERAPAMIL HYDROCHLORIDE (ORIG)
FDAhigh relevance
Entity match (knack); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — VERAPAMIL HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Entity match (verapamil hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BUPROPION HYDROCHLORIDE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METFORMIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METFORMIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — CIPROFLOXACIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — CIPROFLOXACIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DOXEPIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View source

A Phase I Clinical Trial to Evaluate the Pharmacokinetic and Safety of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Mild Hepatic Impairment, Moderate Hepatic Impairment, and No
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Validate the Effect of Calcium Oral Spray on Early Childhood Caries
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Hydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Management of Abdominal Post-surgical Scar With Ozoaqua Versus Standard Care
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Modified Mini-PCNL Versus Standard PCNL for Complex Kidney Stones
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Physical Fitness, Cardiovascular and Brain Health
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Cardiometabolic Effects of the Recommended Daily Pecan Intake Dose
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Approves Veklury as First Treatment for COVID-19
Humanexa Signalsmedium relevance
Moderate corpus alignment

Effect of oral calcium carbonate on uterine contractility: a pilot randomised controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Safety and efficacy of ashwagen (a standardized withania somnifera extract) in stress and anxiety with hypertension and associated cardiometabolic risk factors: a randomized, placebo-controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Optimizing estradiol serum levels for optimal skeletal and cardiovascular health during transdermal menopausal hormone therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Colorectal cancer care in Uganda: a narrative review and case-based health needs assessment from Mbarara Regional Referral Hospital.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
A global model for symptomatic obstructive hypertrophic cardiomyopathy to assess the cost-effectiveness of mavacamten: results from Dutch societal perspective.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of caffeine gum on same-day and subsequent neuromuscular performance under a standardized resistance-priming condition in male basketball players.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of different caffeine doses on fat oxidation and cardiovascular response during exercise at FATmax in overweight/obese female college students.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Knack
Verapamil Hydrochloride

Commercial impact

medium

The entry of Knack into the Verapamil market may lead to increased competition, potentially affecting revenue and market positioning for current players in the cardiovascular segment.

Regulatory impact

low

The approval of ANDA220076 indicates compliance with FDA standards, but does not suggest immediate regulatory changes for existing products.

What to watch

Monitor market entry timing and initial sales performance of Knack's Verapamil Hydrochloride.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.